Antagonist anti-CD40 monoclonal antibodies and methods for their use

Details for Australian Patent Application No. 2004287879 (hide)

International Classifications

Event Publications

15 June 2006 PCT application entered the National Phase

PCT publication WO2005/044854 Priority application(s): WO2005/044854

20 November 2008 Alteration of Name

The name of the applicant has been altered to Novartis Vaccines and Diagnostics, Inc.

6 January 2011 Application Accepted

Published as AU-B-2004287879

3 February 2011 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 12 Jan 2011. Address for service in Australia - FB Rice & Co Level 23 200 Queen Street Melbourne VIC 3000 2005

2 June 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.